Do analysts prefer TLX or RGC?

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 124.30%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, TLX or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.98 -$7.12M N/A N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is TLX or RGC more profitable?

Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Regencell Bioscience N/A N/A N/A

Does the media favor TLX or RGC?

In the previous week, Regencell Bioscience had 15 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 18 mentions for Regencell Bioscience and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.63 beat Regencell Bioscience's score of 0.11 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, AXSM or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $638.50M 18.63 -$183.17M -$3.73 N/A Telix Pharmaceuticals $803.79M 3.98 -$7.12M N/A N/A

Does the media prefer AXSM or TLX?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Axsome Therapeutics and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.63 beat Axsome Therapeutics' score of 0.51 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, TLX or RDY?

Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.98 -$7.12M N/A N/A Dr. Reddy's Laboratories $3.58B 3.10 $484.20M $0.58 22.91

Does the media favor TLX or RDY?

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for Telix Pharmaceuticals and 1 mentions for Dr. Reddy's Laboratories. Telix Pharmaceuticals' average media sentiment score of 0.63 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ELAN or TLX?

Telix Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elanco Animal Health $4.72B 2.52 -$232M -$0.50 N/A Telix Pharmaceuticals $803.79M 3.98 -$7.12M N/A N/A

Does the media favor ELAN or TLX?

In the previous week, Elanco Animal Health had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Elanco Animal Health and 3 mentions for Telix Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.15 beat Telix Pharmaceuticals' score of 0.63 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ARWR or TLX?

Arrowhead Pharmaceuticals has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arrowhead Pharmaceuticals $829.45M 12.81 -$1.63M -$2.15 N/A Telix Pharmaceuticals $803.79M 3.98 -$7.12M N/A N/A

Does the media refer more to ARWR or TLX?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Arrowhead Pharmaceuticals and 3 mentions for Telix Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.13 beat Telix Pharmaceuticals' score of 0.63 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Telix Pharmaceuticals (TLX) Competitors

$9.42 -0.01 (-0.13%)

As of 03:54 PM Eastern

Compare

TLX vs. RGC, AXSM, RDY, ELAN, and ARWR

Should you buy Telix Pharmaceuticals stock or one of its competitors? MarketBeat compares Telix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telix Pharmaceuticals include Regencell Bioscience (RGC), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Telix Pharmaceuticals compare to Regencell Bioscience?

Telix Pharmaceuticals (NASDAQ:TLX) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Regencell Bioscience had 15 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 18 mentions for Regencell Bioscience and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.63 beat Regencell Bioscience's score of 0.11 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 124.30%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Regencell Bioscience has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.98	-$7.12M	N/A	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Telix Pharmaceuticals has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Regencell Bioscience	N/A	N/A	N/A

Summary

Telix Pharmaceuticals beats Regencell Bioscience on 6 of the 10 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

Axsome Therapeutics presently has a consensus price target of $251.26, suggesting a potential upside of 8.71%. Telix Pharmaceuticals has a consensus price target of $21.13, suggesting a potential upside of 124.30%. Given Telix Pharmaceuticals' higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.63	-$183.17M	-$3.73	N/A
Telix Pharmaceuticals	$803.79M	3.98	-$7.12M	N/A	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Axsome Therapeutics had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Axsome Therapeutics and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.63 beat Axsome Therapeutics' score of 0.51 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Telix Pharmaceuticals' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Telix Pharmaceuticals	N/A	N/A	N/A

Summary

Axsome Therapeutics and Telix Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Telix Pharmaceuticals (NASDAQ:TLX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.98	-$7.12M	N/A	N/A
Dr. Reddy's Laboratories	$3.58B	3.10	$484.20M	$0.58	22.91

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Telix Pharmaceuticals currently has a consensus target price of $21.13, indicating a potential upside of 124.30%. Dr. Reddy's Laboratories has a consensus target price of $16.90, indicating a potential upside of 27.21%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for Telix Pharmaceuticals and 1 mentions for Dr. Reddy's Laboratories. Telix Pharmaceuticals' average media sentiment score of 0.63 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Telix Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

Telix Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Telix Pharmaceuticals has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Telix Pharmaceuticals	N/A	N/A	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Telix Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.52	-$232M	-$0.50	N/A
Telix Pharmaceuticals	$803.79M	3.98	-$7.12M	N/A	N/A

Elanco Animal Health currently has a consensus price target of $28.20, suggesting a potential upside of 18.73%. Telix Pharmaceuticals has a consensus price target of $21.13, suggesting a potential upside of 124.30%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Elanco Animal Health had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Elanco Animal Health and 3 mentions for Telix Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.15 beat Telix Pharmaceuticals' score of 0.63 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

Summary

Elanco Animal Health beats Telix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Arrowhead Pharmaceuticals has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.81	-$1.63M	-$2.15	N/A
Telix Pharmaceuticals	$803.79M	3.98	-$7.12M	N/A	N/A

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Arrowhead Pharmaceuticals and 3 mentions for Telix Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.13 beat Telix Pharmaceuticals' score of 0.63 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals currently has a consensus target price of $87.80, indicating a potential upside of 16.41%. Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 124.30%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Telix Pharmaceuticals has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Telix Pharmaceuticals' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Telix Pharmaceuticals	N/A	N/A	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Arrowhead Pharmaceuticals beats Telix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.20B	$3.33B	$6.32B	$12.64B
Dividend Yield	N/A	2.28%	2.68%	5.31%
P/E Ratio	N/A	18.16	21.14	26.75
Price / Sales	3.98	329.99	548.19	115.38
Price / Cash	223.65	54.19	27.44	37.60
Price / Book	7.66	6.86	9.92	6.92
Net Income	-$7.12M	$24.15M	$3.56B	$336.84M
7 Day Performance	-0.55%	2.36%	2.24%	4.33%
1 Month Performance	N/A	N/A	N/A	-0.37%
1 Year Performance	-43.79%	63.67%	36.82%	40.73%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.5426 of 5 stars	$9.42 -0.1%	$21.13 +124.3%	-43.7%	$3.20B	$803.79M	N/A	1,184	Gap Up
RGC Regencell Bioscience	0.1383 of 5 stars	$25.80 flat	N/A	N/A	$12.76B	N/A	N/A	10
AXSM Axsome Therapeutics	2.5357 of 5 stars	$235.97 flat	$251.26 +6.5%	+123.5%	$12.14B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	2.8976 of 5 stars	$13.60 0.0%	$16.90 +24.3%	-7.2%	$11.35B	$3.58B	23.44	27,811	Analyst Upgrade
ELAN Elanco Animal Health	4.0961 of 5 stars	$21.77 +0.2%	$28.20 +29.5%	+77.3%	$10.85B	$4.72B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. RGC, AXSM, RDY, ELAN, and ARWR

How does Telix Pharmaceuticals compare to Regencell Bioscience?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. RGC, AXSM, RDY, ELAN, and ARWR

How does Telix Pharmaceuticals compare to Regencell Bioscience?

Does the media favor TLX or RGC?

Do analysts prefer TLX or RGC?

Which has higher earnings & valuation, TLX or RGC?

Which has more risk and volatility, TLX or RGC?

Do insiders & institutionals believe in TLX or RGC?

Is TLX or RGC more profitable?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Which has more risk & volatility, AXSM or TLX?

Do analysts prefer AXSM or TLX?

Which has higher valuation and earnings, AXSM or TLX?

Do institutionals & insiders have more ownership in AXSM or TLX?

Does the media prefer AXSM or TLX?

Is AXSM or TLX more profitable?

Summary

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Which has higher earnings & valuation, TLX or RDY?

Do institutionals and insiders believe in TLX or RDY?

Do analysts rate TLX or RDY?

Does the media favor TLX or RDY?

Is TLX or RDY more profitable?

Which has more volatility & risk, TLX or RDY?

Summary

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Is ELAN or TLX more profitable?

Do insiders and institutionals have more ownership in ELAN or TLX?

Which has better earnings & valuation, ELAN or TLX?

Do analysts prefer ELAN or TLX?

Does the media favor ELAN or TLX?

Which has more risk & volatility, ELAN or TLX?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Which has stronger valuation and earnings, ARWR or TLX?

Which has more volatility & risk, ARWR or TLX?

Does the media refer more to ARWR or TLX?

Do analysts recommend ARWR or TLX?

Is ARWR or TLX more profitable?

Do insiders and institutionals believe in ARWR or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools